Today, Benzinga's options scanner spotted 11 options trades for Abbott Laboratories. This is not a typical pattern. The ...

Q4 2024 Earnings Call Transcript March 6, 2025 Elutia Inc. misses on earnings expectations. Reported EPS is $-0.26 EPS, expectations were $-0.25. Operator: Good afternoon, ladies and gentlemen.

Analysts have recently evaluated Abbott Laboratories and provided 12-month price targets. The average target is $145.12, ...

A groundbreaking leadless pacemaker implantation in a complex congenital heart case—exploring an innovative approach to ...

A Bakersfield hospital Monday became the first in Kern County to successfully implant the AVEIR DR, the world's first dual-chamber leadless pacemaker system from Abbott that treats people with ...

Abbott manufactures and markets cardiovascular ... and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents ...

Products include pacemakers, implantable cardioverter defibrillators ... and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United ...

Case marks the beginning of a multi-site pivotal trial to evaluate Abbott’s system for management of treatment-resistant ...

After decades of development and trials, Medtronic has secured U.S. Food and Drug Administration approval for adaptive ...

I was born with an enlarged heart and congestive heart failure (CHF)—a chronic condition that makes the heart less efficient ...

A team of experts from the Icahn School of Medicine at Mount Sinai has become the first in the United States to perform a ...

Abbott NORTHAMPTON, MA / ACCESS Newswire ... company's investigational AVEIR™ Conduction System Pacing (CSP) leadless pacemaker system, as part of a feasibility study. These procedures mark ...